Less than a week after president Obama proposed a spending freeze on non-security related federal programs, the FDA released its fiscal year 2011 budget request, calling for a 23% increase.
Less than a week after president Obama proposed a spending freeze on non-security related federal programs, the FDA released its fiscal year 2011 budget request, calling for a 23% increase. The FDA is asking for a total of $4.03 billion in FY 2011 “to promote and protect public health,” according to an agency release.
The FDA’s FY 2010 budget included a 19% increase over FY 2009 and totaled $3.28 billion. The new proposed budget, which would begin 1 October 2010, would include a $146-million increase in budget authority and $601 million in industry user fees. Of these user fees, approximately $667 million would be derived from the Prescription Drug User Fee Act (PDUFA) and, if the related legislation is passed, $38 million would come from human generic drug fees. If the President’s spending freeze goes through, this overall budget increase would enable the FDA as a non-security discretionary federal program to have a budget of $4.03 billion for the fiscal years 2011, 2012 and 2013.
“The budget request reflects the FDA’s resolve to transform food safety practices, improve medical product safety, protect patients, and modernize FDA regulatory science to advance public health,” says the release. FY 2011 funding would also go toward the agency’s new regulatory authority over tobacco products, including cigarettes (see back story, “FDA Opens Center for Tobacco Products”).
Specifically, FDA intends to focus FY 2011 funds on four initiatives, according to the agency release:
The FY 2011 Health and Human Services (HHS) budget also includes $302 million for “ongoing pandemic influenza preparedness activities” within the Centers for Disease Control and Prevention, the National Institutes of Health (NIH), theFDA, and the Office of the Secretary. In addition, remaining balances from the $7.65 billion that Congress appropriated to HHS last June for H1N1 swine-flu and pandemic influenza preparedness and response would carry over to the FY 2011 budget. These balance funds would specifically go toward HHS development of “cell-based and recombinant vaccines, antivirals, respirators, and other activities to help prepare for future potential pandemics,” according to the budget proposal.
Of note, the proposal calls for $39 million in budget authority for the FDA to consolidate at its headquarters at the White Oak (MD, USA) location and $112 million to repair and maintain FDA-owned facilities throughout the US.
Finally, NIH would be appropriated an increase of $1 billion for a total of $32.2 billion to support innovative biomedical research projects.
Click here to read President Obama’s full FY 2011 budget proposal for HHS.
Click here to read a related blog post: "Federal Spending Freeze Could Threaten Supply-Chain Security”
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.